8-K: Avalo Therapeutics Completes Phase 2 Enrollment, Extends Cash Runway

Avalo Therapeutics announced the completion of enrollment for its Phase 2 LOTUS trial for AVTX-009, with topline data expected mid-2026, and reported a cash runway into 2028.

Summary

• Completed enrollment in the Phase 2 LOTUS trial for AVTX-009, targeting moderate to severe hidradenitis suppurativa.
• Topline data from the LOTUS trial is anticipated in mid-2026.
• Cash, cash equivalents, and short-term investments totaled $111.6 million as of September 30, 2025.
• Current cash resources are expected to fund operations into 2028.
• Reported a net loss of $30.6 million for the third quarter of 2025, compared to a net income of $23.0 million in the third quarter of 2024.
• Basic and diluted net loss per share was $2.19 for Q3 2025, a decrease from basic net income per share of $0.98 in Q3 2024.
• Research and development expenses increased by $4.1 million to $13.6 million in Q3 2025, primarily due to costs associated with the Phase 2 LOTUS trial.
• General and administrative expenses rose by $1.3 million to $5.6 million in Q3 2025, mainly due to stock-based compensation.
• The significant change in net income/loss was largely due to a $47.3 million change in other expenses related to warrants from a March 2024 private placement, which were fully exercised in 2024.
• Kevin Lind was appointed to the Board of Directors.
• Taylor Boyd was appointed Chief Business Officer and Ashley Ivanowicz as Senior Vice President, Human Resources.

Sentiment

Score: 5

Explanation: The completion of Phase 2 enrollment and extended cash runway are positive operational milestones, but these are significantly offset by a substantial net loss and increased expenses compared to the prior year, indicating ongoing high burn rate for clinical development.

Positives

• Completion of enrollment for the Phase 2 LOTUS trial for AVTX-009, a significant step towards potential market entry for a treatment for hidradenitis suppurativa.
• Extended cash runway into 2028, providing financial stability for ongoing operations and clinical development.
• Strengthened leadership team with key appointments in business development and human resources, and a new board member with extensive financial and corporate strategy experience.

Negatives

• Reported a net loss of $30.6 million for Q3 2025, a significant decline from a net income of $23.0 million in Q3 2024.
• Basic and diluted net loss per share of $2.19 for Q3 2025, compared to basic net income per share of $0.98 in Q3 2024.
• Increased research and development expenses by $4.1 million to $13.6 million in Q3 2025, driven by clinical trial costs.
• Increased general and administrative expenses by $1.3 million to $5.6 million in Q3 2025, primarily due to stock-based compensation.
• Total current assets decreased from $138.890 million at December 31, 2024, to $113.846 million at September 30, 2025.
• Total stockholders' equity decreased from $133.032 million at December 31, 2024, to $91.547 million at September 30, 2025.
• Significant increase in non-current derivative liability from $8.120 million at December 31, 2024, to $23.160 million at September 30, 2025.

Risks

• Drug development costs and the timing of trials and trial results.
• Reliance on investigators and enrollment of patients in clinical trials.
• Reliance on key personnel.
• Regulatory risks.
• General economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East.

Future Outlook

Avalo Therapeutics expects topline data from its Phase 2 LOTUS trial for AVTX-009 in mid-2026 and is progressing with Phase 3 planning. The company anticipates its current cash, cash equivalents, and short-term investments will fund operations into 2028.

Management Comments

• "Now that enrollment is complete, we're fully focused on completing the LOTUS trial, preparing for the data readout in mid-2026, and progressing our Phase 3 planning."
• "This marks an important transition for Avalo as we turn our focus from enrollment to completion of the trial, guided by strong conviction in AVTX-009's high-affinity inhibition of IL-1 and its potential to deliver meaningful benefit for people living with hidradenitis suppurativa."

Industry Context

Avalo Therapeutics operates in the competitive clinical-stage biotechnology sector, focusing on IL-1-based treatments for immune-mediated inflammatory diseases. The completion of Phase 2 enrollment for AVTX-009 in hidradenitis suppurativa positions the company to potentially address a significant unmet medical need, as HS is a chronic, debilitating condition affecting a notable percentage of the U.S. population. Success in this trial could validate their IL-1 inhibition approach and differentiate them in a market with existing and emerging therapies for inflammatory conditions.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential for future value creation if AVTX-009's Phase 2 trial yields positive results, but current financial performance shows a significant net loss and increased expenses, which could impact short-term sentiment. The extended cash runway provides stability.
• Employees: Expanded leadership team indicates growth and strategic focus, potentially positive for employee morale and opportunities.
• Patients (with Hidradenitis Suppurativa): Progress in the LOTUS trial offers hope for a new treatment option for a debilitating disease.
• Creditors: The extended cash runway into 2028 suggests reduced short-term liquidity concerns.

Next Steps

• Complete the Phase 2 LOTUS trial.
• Prepare for the topline data readout in mid-2026.
• Progress with Phase 3 planning for AVTX-009.
• Explore additional opportunities in prevalent indications with unmet needs.

Key Dates

Recommendation

While the completion of Phase 2 enrollment for AVTX-009 and the extended cash runway into 2028 are positive operational and financial stability indicators for a clinical-stage biotech, the significant net loss of $30.6 million in Q3 2025, a reversal from net income in the prior year, and increased operating expenses warrant caution. The stock's future performance is heavily reliant on the mid-2026 topline data from the LOTUS trial. Until then, the current financial burn rate and the binary nature of clinical trial results suggest a 'hold' position, awaiting further clarity on the drug's efficacy and safety profile.

Keywords

Avalo Therapeutics, AVTX, Biotechnology, Clinical Stage, IL-1, AVTX-009, Hidradenitis Suppurativa, HS, LOTUS trial, Phase 2, Clinical Trial Data, Financial Results, Q3 2025, Cash Runway, Drug Development, Inflammatory Diseases, Immune-mediated